FDA Approves New Formulation Of Merck’s Antifungal Agent Noxafil

Merck & Co. March 14 announced that the Food and Drug Administration has approved Noxafil (posaconazole) injection (18 mg/mL), a new formulation of Noxafil for intravenous (IV) use.

Merck’s antifungal agent also is marketed as Noxafil (100 mg) delayed-release tablets and Noxafil (40 mg/mL) oral suspension, the Whitehouse Station, N.J.-based company said.

Noxafil injection, delayed-release tablets and oral suspension are indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with ...